A new gene therapy, a procurement process gone wrong, and backing away from a biosimilar… What’s new for pharma in business?
Stephanie Sutton |
- The FDA has cleared 23andMe’s Personal Genome Service Pharmacogenetic Reports for the inclusion of information about genetic variants that may impact a patient’s ability to metabolize some medicines. The test does not describe an association between the detected variants and any specific drug, nor whether a person will or will not respond to a particular drug. It is intended to help inform discussions with healthcare providers.
- A new gene therapy has been recommended for approval in Europe. Luxturna can be used in adults and children suffering from retinal dystrophy – an inherited disorder caused by RPE65 gene mutations, which usually leads to blindness. Novartis will be required to conduct follow ups on patients to ensure long-term safety and efficacy.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine